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Background: ABCB1 is responsible for multidrug resistance, the principal mechanism by which many cancers
develop resistance to chemotherapeutic drugs. There is a controversy whether ABCB1 gene polymorphisms correlate
with survival and response in cancer patients treated with chemotherapy. We evaluated the association between
clinical outcome (safety and efficacy) of paclitaxel monotherapy in metastatic breast cancer patients with ABCB1 gene
polymorphisms 2677G>T/A or 3435C>T.
Patients and methods: Patients with metastatic breast cancer were treated with 175 mg/m2 paclitaxel per 3-week
cycle. Peripheral blood mononuclear cells from patients were used to genotype ABCB1 2677G>T/A and 3435C>T
polymorphisms. Genotypes were investigated for their association with tumor response, survival, toxicity, and
chemoresistance.
Results: ABCB1 3435 CT showed a significantly lower disease control rate than the CC genotype (P = 0.025).
ABCB1 3435 CT was correlated with shorter overall survival (OS) in Cox regression analysis (P = 0.026). The 2677 GG
genotype showed a significant association with chemoresistance to paclitaxel and anthracycline (P = 0.04 and 0.04,
respectively). None of the ABCB1 genotypes correlated with toxicity.
Conclusions: ABCB1 genotypes may be a predictor of paclitaxel activity as well as a prognostic factor in metastatic
breast cancer patients.
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background
Paclitaxel is an effective agent in the treatment of metastatic
breast cancer. It seems particularly promising because it has
elicited impressive response rates as second- and third-line
therapy [1]. Paclitaxel has been reported to elicit a response rate
of 20%–62% as a first-line therapy and 4%–32% in previously
treated patients [2]. Chemotherapy resistance is a major
obstacle to successful treatment and several potential
mechanisms have been reported to account for resistance to
paclitaxel. These are decreased sensitivity to apoptosis-inducing
stimuli, alterations in tubulin binding and microtubule
dynamics, and overexpression of the transporter protein
P-glycoprotein (P-gp) [3].
In searching for an answer to the multidrug resistance
phenotype, many studies have been focused on the ABCB1
gene. It encodes P-gp, a transmembrane protein that acts as an
energy-dependent drug efflux pump for chemotherapeutic
drugs commonly used in metastatic breast cancer, including
doxorubicin and taxanes [4]. More than 50 single-nucleotide
polymorphisms (SNPs) and three insertion/deletion
polymorphisms have been reported in the ABCB1 gene and
some of these variants affect the expression and function of P-
gp [5, 6]. Hoffmeyer et al. found that ABCB1 gene
polymorphism could affect P-gp function. They indicated that
a synonymous SNP in exon 26, 3435C>T, correlated with the
level of P-gp expression in the intestine. Individuals
homozygous for this SNP had lower P-gp expression and
showed higher plasma levels of the P-gp substrate digoxin [7].
Tanabe et al. [8] also found a nonsignificant trend for placental
P-gp expression in relation to polymorphisms at position 2677
(GG>G/mut>mut/mut). SNP of ABCB1 may increase the efflux
of antineoplastic agents from cancer cells or increase
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elimination from the body, resulting in lower plasma
concentrations, thereby influencing their therapeutic efficacy.
On the basis of this information, we carried out an
association study between clinical outcome of paclitaxel
monotherapy (efficacy and safety) and the ABCB1 gene
polymorphisms 2677G>T/A and 3435C>T in metastatic
breast cancer patients.
patients and methods
patients
Women with histologically confirmed breast cancer were eligible for
enrollment. They were required to be nonpregnant (‡18 years of age), have
an Eastern Cooperative Oncology Group performance status of 0–2, and
a life expectancy of >12 weeks. Prior chemotherapy was permitted if
completed at least 4 weeks before entry into the study. Prior taxane
therapies were not allowed, but prior hormonal therapy, immunotherapy,
and localized radiotherapy were permitted.
All patients were required to have clinically or radiographically
measurable disease and to have adequate renal, hepatic, and bone marrow
function defined as follows: serum creatinine £1.5 · upper normal limit
(UNL), total bilirubin £ 1.5 · UNL, absolute neutrophil count ‡ 1.5 · 109/l,
platelet count ‡ 100 · 109/l, AST and ALT £ 3.0 · UNL, and alkaline
phosphates £ 3.0 · UNL. Pretreatment evaluation was carried out within
4 weeks of therapy initiation and included full history, physical
examination, blood cell count, biochemical screening profile, chest X-ray,
and appropriate computed tomography imaging for disease assessment.
Patients were ineligible if they had a history of neoplasm other than
breast cancer (excepting nonmelanomatous skin cancer or curatively
treated cervical carcinoma in situ), a history of ventricular arrhythmias or
congestive heart failure, preexisting motor or sensory neuropathy greater
than grade 1, or any other underlying medical condition that would
hinder study participation. Pregnant or lactating patients and those with
child-bearing potential who did not implement adequate contraceptive
measures were also ineligible.
definition of anthracycline and paclitaxel sensitivity
Anthracycline-refractory disease referred to recurrent disease during
anthracycline-containing adjuvant therapy or disease that never responded
and progressed during palliative anthracycline chemotherapy.
Anthracycline-resistant disease was defined as disease that relapsed within
12 months after anthracycline adjuvant therapy, disease that initially
responded but progressed with therapy, or disease that progressed within
6 months after stopping palliative anthracycline therapy. An anthracycline-
sensitive disease referred to a disease that relapsed 12 months after
anthracycline adjuvant therapy or a disease that progressed 6 months after
stopping palliative anthracycline therapy [9]. Generally, paclitaxel
treatment was done after anthracycline failure and thus, paclitaxel-resistant
disease was defined as a disease that progressed while receiving
paclitaxel or within 3 months of the last administration of paclitaxel.
A paclitaxel-sensitive disease was defined as a disease that progressed
3 months after the last paclitaxel chemotherapy cycle [10].
treatment
Paclitaxel (175 mg/m2) was administered over 3 h every 3 weeks.
Premedications consisted of diphenhydramine, H2 blocker, and
dexamethasone. Treatment continued until disease progression or
occurrence of prohibitive toxicity. In the event of grade 3–4 hematologic
toxicity, treatment was delayed until recovery. For all non-hematologic
grade 3 toxic effects, treatment was held until toxicity recovered to grade 1.
response and toxicity assessment
Tumor response measurements were made according to the Response
Evaluation Criteria in Solid Tumors every two cycles and all responses had
to be confirmed by a second measurement after an additional 4 weeks.
Complete blood cell counts and toxicity assessments were carried out
weekly, and performance status and serum chemistry were assessed
before each cycle. Toxicity was evaluated according to National Cancer
Institute Common Toxicity Criteria (version 3.0).
genotyping
Peripheral blood mononuclear cells were isolated from blood using
Ficoll-Paque (Pharmacia, Uppsals, Sweden) following the manufacturer’s
instructions. Genomic DNA (gDNA) from lymphocytes was extracted
with the LaboPass Blood kit (Genotein Biotech, Seoul, Korea). Extracted
gDNA was amplified by PCR using an Eppendorf Mastercycler Gradient
(Brinkmann Instruments, Inc., New York, USA). PCR cycling was done
with an initial denaturation at 95C for 2 min followed by 30 cycles of
denaturation at 94C for 30 s, annealing at 57C for 20 s, and extension at
72C for 30 s. Forward (F) and reverse (R) primers were designed on the
basis of target gene sequences obtained from GenBank: ABCB1 2677G>T/A:
5#-ATTGCAATAGCAGGAGTTGT-3#(F), 5#-
CTGGCTTTGCTACTTTCTGT-3#(R) and 3435C>T: 5#-
ACAATTATGACCTTGTTGGG-3#(F), 5#-TTCTCTTCACTTCTGGGAGA-
3#(R). Sequencing of PCR products was carried out according to the
manufacturer’s instructions using the CEQ 8000 Dye Terminator Kit
(CEQ 8000, Beckman Coulter, Inc., Fullerton, CA, USA). Sequence data
were analyzed and compared using the GeneDoc system (www.psc.edu/
biomed/genedoc) and FinchTV software.
statistical methods
The haplotype frequency of ABCB1 was estimated by the expectation-
maximization algorithm, PHASE version 2.0 (http://
www.stat.washington.edu/stephens/software.html). The significance of the
differences in genotypes between chemoresistant and sensitive patients was
calculated using a Fisher’s exact test. Progression-free survival (PFS) was
defined as the time interval between the date of the first administration of
paclitaxel and the date of disease progression or the date of death as
a result of any cause. For PFS analyses, patients were censored at the time
of last clinical contact if they were lost to follow-up, did not experience
disease progression, or died before the cut-off date for the analyses. Patients
were also censored on the date they received any subsequent anticancer
therapy. Overall survival (OS) was calculated from the date of the first
administration of paclitaxel to the date of death or the date of last contact
(censored observation). The Kaplan–Meier method was used to estimate
the distribution of time to events. Cox regression analysis was applied to
determine the contribution of polymorphisms and other factors to survival
rate. The following characteristics were included for the Cox regression
analysis of prognostic factors: age, performance status, hormone receptor
status, number of previous regimens, prior history of anthracycline
treatment, anthracycline resistance, number of metastatic sites, response
to paclitaxel, and ABCB1 2677G>T/A and 3435C>T genotypes. A logistic
regression model was used to calculate the odds ratio and the
corresponding 95% confidence interval (CI).
results
patient characteristics
Characteristics of 121 patients treated from September 1998 to
August 2005 are listed in Table 1. The majority (85%) of
patients had received prior anthracycline chemotherapy, either
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as adjuvant treatment (54 patients) or as therapy for metastatic
disease (49 patients). There were 9 anthracycline-refractory
patients, 40 anthracycline-resistant patients, and 54
anthracycline-sensitive patients.
ABCB1 genotype was examined in 108 patients (89.3%),
whose gDNA could be extracted from peripheral blood cells.
Frequencies of the ABCB1 2677 GG, GT, GA, TT, TA, and AA
genotypes were 21.3%, 27.8%, 16.7%, 14.8%, 14.0%, and 3.3%,
respectively. Frequencies of the ABCB1 3435 CC, CT, and TT
genotypes were 50.9%, 10.2%, and 38.9%, respectively.
Frequencies of the 2677G–3435C, 2677G–3435T, 2677T–
3435C, 2677T–3435T, 2677A–3435C, and 2677A–3435T
haplotypes were 24.5%, 19.0%, 20.4%, 11.6%, 10.6%, and
13.9%, respectively.
association with tumor response and disease
control rate
The median number of treatment cycles was 6 (range 1–16),
with a total of 713 cycles. The median relative dose intensity of
paclitaxel was 0.89 (range 0.29–1.00). Of the 121 patients
enrolled, 113 were fully eligible for response evaluation. Eight
patients were unevaluable because of treatment refusal (two
patients) and treatment discontinuation before the first
scheduled response evaluation (six patients). There were five
complete responses and 24 partial responses, for an overall
response rate of 25.6%.
The ABCB1 3435 genotypes were associated with disease
control rate (50% in CT, 84.9% in CC and 77.5% in TT: CT
versus CC, P = 0.025). The disease control rate of paclitaxel
was also affected by a patient’s sensitivity to anthracycline
(anthracycline refractory versus sensitive; 50.0% versus 84.3%,
P = 0.04, anthracycline-resistant versus sensitive; 63.9%
versus 84.3%, P = 0.04). In contrast, the ABCB1 2677
genotype and haplotypes did not correlate with response rate
or disease control rate (Table 2).
association with survival
The median time to progression and median OS was
5.7 months (95% CI = 4.6–6.8) and 18.1 months (95%
CI = 12.5–23.8), respectively.
There was no difference in PFS among ABCB1 3435
genotypes. In multivariate analysis for PFS, response to
paclitaxel and anthracycline resistance was independent
prognostic factors [response to paclitaxel hazard ratio (HR) =
1.81, 95% CI = 1.02–3.21, P = 0.042; anthracycline refractory
HR = 3.49, 95% CI = 1.35–9.06, P = 0.01]. In contrast, patients
with the ABCB1 3435 CT genotype showed a tendency towards
shorter OS than patients with the CC genotype (13.6 versus
18.5 months, P = 0.06). In multivariate analysis for OS, the
ABCB1 3435 genotype was an independent prognostic factor.
The HR of the 3435 CT genotype was 3.51 (95% CI =
1.16–3.51, P = 0.026). Response to paclitaxel, anthracycline-
resistance, the number of metastatic sites, and age also were
Table 1. Patient characteristics
Characteristic Number of
patients
%
Number of enrolled patients 121
Age (years), median (range) 49 (32–71)
Eastern Cooperative Oncology
Group performance status
0 19 15.7
1 58 47.9
2 44 36.4
Dominant site of disease
Soft tissue 15 12.4
Osseous 16 13.2
Visceral 90 74.4
Number of metastasis site
1 37 30.6
2 54 44.6
3+ 30 24.8
Hormone receptor status
Positive 80 66.1
Negative 23 19.0
Unknown 18 14.9
Prior chemotherapy
Adjuvant therapy only 68 56.2
Palliative therapy only 25 20.7
Both adjuvant and palliative 26 21.5
No prior therapy 2 1.6
Prior chemotherapy with
anthracycline (n = 103)
Adjuvant therapy 54 52.4
Palliative therapy 49 47.6
Table 2. Comparison of response and disease control rates according to
clinical and pathologic characteristics and genotypes
Characteristic RR (%) P value DCR (%) P value
Paclitaxel treatment
First line 24/66 (36.3) 0.002 54/66 (81.8) >0.05
Second line 5/47 (10.6) 32/47 (68.1)
Prior history of anthracycline
No 9/18 (50.0) 0.017 16/18 (88.9) >0.05
Yes 20/95 (21.0) 70/95 (73.7)
Resistance to anthracycline
Refractory 0/8 (0) <0.001 4/8 (50.0) 0.024
Resistant 2/36 (5.5) 23/36 (63.9)
Sensitive 18/51 (35.2) 43/51 (84.3)
ABCB1 2677 G>T/A
GG 5/23 (21.7) >0.05 17/23 (73.9) >0.05
GT + GA 15/44 (34.0) 36/44 (81.8)
TT + TA + AA 8/36 (22.2) 28/36 (77.8)
ABCB1 3435C>T
CC 12/53 (22.6) >0.05 45/53 (84.9) 0.04
CT 4/10 (40.0) 5/10 (50.0)
TT 12/40 (30.0) 31/40 (77.5)
ABCB1 haplotypes
2677G–3435C 13/51 (25.4) >0.05 40/51 (78.4) >0.05
Others 43/155 (27.7) 122/155 (78.7)
CR, complete response; PR, partial response; SD, stable disease; RR,
response rate (CR + PR); DCR, disease control rate (CR + PR + SD).
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independent prognostic factors (response to paclitaxel HR =
2.48, 95% CI = 1.05–5.83, P = 0.037; anthracycline resistant
HR = 5.03, 95% CI = 2.30–10.9, P < 0.001, the number of
metastatic sites HR= 2.09, 95% CI = 1.01–4.31, P = 0.045;
age, HR= 3.14, 95% CI = 1.31–7.50, P = 0.01).
Neither the ABCB1 2677G>T/A genotype nor the ABCB1
2677/3435 haplotypes correlated with PFS or OS.
association between ABCB1 genotypes and
chemotherapy resistance
The distribution of ABCB1 2677G>T/A and 3435C>T
genotypes according to chemotherapy sensitivity is shown in
Table 3. The 2677 GG genotype was more frequent in
paclitaxel-resistant patients than other 2677 genotypes (GG
versus GT + GA, P = 0.028; GG versus others, P = 0.04). Other
factors associated with paclitaxel sensitivity were anthracycline-
resistance, previous treatment, and the number of metastatic
sites (anthracycline-resistant versus sensitive, 11.1% versus
45.0%, P = 0.001; paclitaxel first-line versus second-line, 39.3%
versus 19.1%, P = 0.02; one metastatic site versus multiple
metastatic sites, 47.0% versus 24.0%, P = 0.02). The 2677 GG
genotype was also more frequent in anthracycline-refractory
patients than other 2677 genotypes (P = 0.04). Polymorphisms
of ABCB1 3435C>T or ABCB1 2677/3435 haplotypes did not
correlate with resistance to anthracycline or paclitaxel.
association with toxicity
Toxicity evaluation was available for all patients. Grade 3 or 4
neutropenia occurred in 36 patients (29.7%). Grade 3 anemia
was observed in three patients (2.4%), and five patients
experienced grades 3 and 4 thrombocytopenia (4.1%). Grade 3
neuropathy was encountered in 12 patients (9.9%), and no
patient experienced grade 4 neuropathy. Grade 3 arthralgia/
myalgia occurred in 5.8% of patients. Other grade 3 non-
hematologic toxic effects were quite uncommon, occurring in
no >2% of patients. Grade 4 non-hematologic toxicity was
limited to one patient who experienced a severe infection.
No association was observed between the frequency of grade
3–4 hematologic or non-hematologic toxicity and ABCB1
2677G>T/A, 3435C>T genotypes or their haplotypes.
discussion
We evaluated the association between clinical outcome (efficacy
and safety) of paclitaxel monotherapy (175 mg/m2 every 3
weeks) and ABCB1 2677G>T/A or 3435C>T polymorphisms
in patients with metastatic breast cancer, including patients
who were treated with <6 cycles of chemotherapy. If we
select patients with >6 cycles of treatment, it could be too
selective in a clinical setting in predicting the patient’s clinical
outcome before treatment. We observed that ABCB1 3435
genotypes were significantly associated with disease control
rate and this was also shown in patients who were treated with
£6 cycles of paclitaxel (data not shown). As most of the
metastatic breast cancer patients during the period of our study
received paclitaxel-based combination chemotherapy with
gemcitabine or other agents in clinical trials, the number of
patients treated with paclitaxel monotherapy was fairly small.
Some studies have shown that selection of cells for resistance
to either paclitaxel or doxorubicin can result in cross-resistance
to both drugs [11, 12]. Moreover, less than one-half of
breast cancer patients respond to paclitaxel after failing
anthracycline chemotherapy [13]. Meta-analysis revealed
a significant difference in the time to progression between
women who had received prior anthracycline treatment and
those who had not [14]. In our study, anthracycline-sensitive
patients were more sensitive to paclitaxel than anthracycline-
resistant patients. In vitro studies have shown that resistance
to anthracycline may imply resistance to paclitaxel [15, 16].
A cDNA microarray study reported that approximately
one-third of genes that changed expression after paclitaxel
selection exhibited similar changes in expression after
doxorubicin selection (and vice versa) [17]. In our study,
resistance to both anthracycline and paclitaxel correlated with
the ABCB1 2677 GG genotype, and this result indicates one
possible explanation for cross-resistance to anthracycline and
paclitaxel in the treatment of metastatic breast cancer. Guo
et al. [15] reported that cells selected for resistance to
doxorubicin and paclitaxel showed dramatically higher levels of
ABCB1 mRNA than those of wild-type cells. Kars et al. [18]
reported that cell lines resistant to paclitaxel or doxorubicin
expressed both P-gp and ABCB1 genes. These findings may help
to individualize paclitaxel- and anthracycline-based
Table 3. Paclitaxel and anthracycline resistance according to ABCB1 2677 and 3435 genotypes
2677 3435
GG GT + GA TT + TA + AA CC CT TT
Paclitaxel (n = 103)
Sensitive (%)a,b 3 (9.4) 18 (56.3) 11 (34.3) 15 (46.9) 4 (12.5) 13 (40.6)
Resistant (%)a,b 20 (28.2) 27 (38.0) 24 (33.8) 38 (53.5) 7 (9.8) 26 (36.7)
Anthracycline (n = 91)
Sensitive (%)c 6 (12.5) 22 (45.8) 20 (41.7) 24 (50.0) 4 (8.3) 20 (41.7)
Resistant (%) 6 (17.7) 18 (52.9) 10 (29.4) 19 (55.9) 3 (8.8) 12 (35.3)
Refractory (%)c 4 (44.5) 3 (33.3) 2 (22.2) 4 (44.5) 2 (22.2) 3 (33.3)
aP = 0.028 for 2677 GG versus GT + GA, P > 0.05 for 3435C>T.
bP = 0.04 for 2677 GG versus GT + GA or TT + TA + AA.
cP = 0.04 for 2677 GG versus GT + GA or TT + TA + AA, P > 0.05 for 3435C>T.
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chemotherapy in patients with breast cancer. For example,
patients with chemoresistant ABCB1 genotypes might be
initially treated with new agents that evade the mechanism of
ABCB1, such as epothilones and capecitabine [19].
Alternatively, an ABCB1 modulator or a hammerhead
ribozymes against the ABCB1 gene and ABCB1-targeted
antisense oligonucleotides might be used to increase the
therapeutic benefits in patients with an ABCB1 genotype such
as 2677 GG [20, 21].
P-gp expression and ABCB1 3435C>T polymorphism has
been previously identified as an independent factor for disease-
free survival and the response rate to chemotherapy in breast
cancer [22–24]. We found that breast cancer patients with
heterozygous expression of the ABCB1 3435C>T gene had
lower disease control rates and a tendency towards shorter
OS than homozygous patients. Several studies have reported
higher bioavailability of ABCB1 substrates in carriers of T
allele at 3435C>T locus, attributed to lower functional activity
of the protein. 3435C>T polymorphism is associated with
a certain changes in P-gp expression, although in transfection
studies of cells, no differences in either mRNA or protein
levels were observed [25]. Illmer et al. [26] reported that
acute myeloid leukemia patients with heterozygous variant
had increased survival than homozygotes (3435 CC, P < 0.01;
3435 TT, P = 0.05). Similar results on genotype-survival
relation were obtained in one previous study that showed
a tendency to higher survival rate in heterozygotes of
ABCB1 2677G>T/A than homozygotes (P = 0.02) [27].
ABCB1 3435 CT, heterozygous variant could have a greater
effect on P-gp by changing the timing of cotranslational
folding and resulted in altered function, than homozygous
genotypes. This contradictory result may indicate that SNPs
of the ABCB1 gene should be analyzed according to
complete haplotypes. Given the modest sample size of
patient analyzed, this finding should be considered
exploratory in nature. A study with a larger sample size
must be carried out to make definite conclusions.
Paclitaxel treatment in our study was continued until
cancer progression or patient’s refusal from toxicity. After
discontinuation of paclitaxel, we changed to other regimen in
61.9% of the patients and, the remaining patients did not
get any more treatment (data not shown). The continuous
treatment with paclitaxel may up-regulate the pump which
affects efficacy or toxicity of the subsequent treatment. On the
other hand, we speculated that ABCB1 could have a prognostic
role as well as a predictive value. Some studies reported that the
alteration of ABCB1 expression could be associated with
a decreased activity of natural killer and CD8+ cells, which are
involved in the regulation of immune response and in the
killing of tumor cells [28]. Evidence indicated that cell lines
expressing high levels of P-gp were less sensitive to caspase-
mediated apoptosis induced by a wide range of death
stimuli [29]. Nordgard et al. [30] reported that ABCB1 was
associated with a chance of acquiring a mutation in the TP53
gene. Taken together, we thought that the effect of ABCB1
genotype on the survival probability of breast cancer patients
could be related with P-gp action, and not just with drug efflux
function. Further investigations should be made to address the
relationship between ABCB1 genotype and clinical outcome.
Taken together, our results reveal an association of the
ABCB1 polymorphism with chemoresistance and the survival
of metastatic breast cancer patients. In our study, two patients
with a haplotype of 2677 GG and 3435 CT showed significantly
lower disease control rate and shorter OS and PFS (data not
shown). A controlled, prospective trial of adjuvant
chemotherapy with taxane, doxorubicin, and
cyclophosphamide or doxorubin and cyclophosphamide
followed by taxane in breast cancer patients on the basis of the
ABCB1 genotype is warranted. In conclusion, an association
was found between chemotherapy resistance (both
anthracycline and paclitaxel) and the ABCB1 2677 GG
genotype. Patients with the ABCB1 3435 CT genotype showed
lower disease control rate and shorter OS in response to
paclitaxel monotherapy. These results indicate that ABCB1
genotypes could be used to predict chemotherapeutic
resistance and may be a prognostic factor for OS in patients
receiving paclitaxel for metastatic breast cancer.
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